Pfizer Names Jeremy Forman Chief AI, Data & Analytics Officer
My focus will be on how we integrate AI and data excellence across our entire enterprise to drive value, speed, and better outcomes for the millions of people we serve"
Pfizer has promoted Jeremy Forman as Chief AI, Data, & Analytics Officer, according to his LinkedIn announcement on February 3, 2026.
Forman isn't new to Pfizer. From March 2024, he served as Vice President of Global R&D AI, Data, and Analytics, where he built responsible AI cultures and scalable data products powering drug discovery, development, decision intelligence, and operational efficiency.
Before Pfizer, Forman was Executive Director of AI & Data Strategy at Seagen. He spent over seven years at the Bill & Melinda Gates Foundation in senior roles including Director of Global Data & Analytics and Chief Enterprise Architect.
He also held multiple enterprise architecture leadership positions at Oracle and began his career in technical and systems roles at Los Alamos National Laboratory and the New Mexico Department of Transportation.
Forman's promotion comes as Pfizer accelerates AI across drug discovery, development, and operations. In his new role, he will integrate AI and data excellence across Pfizer's entire enterprise.
Forman's mandate spans technological innovation and organizational culture. His LinkedIn post highlights the dual focus.
"My focus will be on how we integrate AI and data excellence across our entire enterprise to drive value, speed, and better outcomes for the millions of people we serve. And while technology is a critical enabler, this work is equally about the culture, strategy, and systems that empower us to deliver breakthroughs that change patients' lives," said Forman.
Forman also serves as Adjunct Lecturer at University of Iowa Tippie College of Business since 2022, teaching data leadership, data strategy, and ethical data use.
Traditional pharma organizations accustomed to long validation cycles face pressure to adapt. Forman's enterprise-wide mandate signals Pfizer will prioritize whoever can deliver AI impact fastest.
Forman's R&D AI track record proved scalable AI works operationally at Pfizer. His challenge is scaling that across Pfizer's entire global enterprise.
“AI is more than automating science, it's amplifying human scientific creativity to accelerate drug discovery and bring therapies to patients globally,” said Forman.